BCL2 and non-small cell lung carcinoma: We found that the combined treatment of NSCLC cells with APG and TRAIL noticeably increased the levels of Bax and Bad with a prominent reduction of Bcl-2 and Bcl-xl levels (Fig. 3d,e).